Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 1;17(2):414-415.
doi: 10.1080/21645515.2020.1781507. Epub 2020 Jul 21.

COVID-19 - Important considerations for developing and using a vaccine

Inayat Ur Rahman  1 , Niaz Ali  1 , Farhana Ijaz  1 , Aftab Afzal  1 , Elsayed Fathi Abd Allah  2
Affiliations
Review

COVID-19 - Important considerations for developing and using a vaccine

Inayat Ur Rahman et al. Hum Vaccin Immunother. .

Abstract

The novel coronavirus SARS-CoV-2 after emerging in China has caused a global pandemic that is risking the lives of millions. COVID-19 has spread across the world at a very rapid rate raising concerns of capacity limitations and lack of unified responses at the global level, particularly from the world's most developed countries. The spread of further infection has been curtailed by lockdown and mass social distancing that has been enforced in most parts of the world. There are no clinical data yet suggesting that any available candidate vaccine will be effective for COVID-19 which will be a critical need for eventually preventing this disease. Extensive research is underway with some success in identification of monoclonal antibodies from COVID-19 recovered patients, which may inform on vaccine development. The clinical evaluations of COVID-19 vaccines need to follow standardized protocols that are essential for safeguarding humans. In absence of a vaccine or a widely available effective therapy, quarantine and other preventive measures are essential in curtailing the risk of pandemic spread.

Keywords: COVID-19; Coronavirus; SARS-CoV-2; global pandemic; vaccine.

PubMed Disclaimer

References

    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. doi: 10.1016/S0140-6736(20)30566-3. - DOI - PMC - PubMed
    1. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, et al. Aerosol and surface stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564–67. doi: 10.1056/NEJMc2004973. - DOI - PMC - PubMed
    1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99. doi: 10.1056/NEJMoa2001282. - DOI - PMC - PubMed
    1. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, Ng O-T, Marimuthu K, Ang LW, Mak TM, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. Jama. 2020;323(15):1488. doi: 10.1001/jama.2020.3204. - DOI - PMC - PubMed
    1. World Health Organization (WHO) . Coronavirus disease 2019 (COVID-19) situation report – 66. [accessed 2020 March26]. https://www.who.int/docs/default-source/coronaviruse/situation-reports/2...

MeSH terms